Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Electrolyte and fluid replacement; dextrose provides caloric support.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Fluid and electrolyte replenishment,Correction of metabolic acidosis,Intravenous source of calories
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable; components are endogenous substances. Dextrose has a plasma half-life of approximately 1.5-2.5 hours in normal glucose metabolism; electrolytes have half-lives dependent on renal function (e.g., sodium half-life ~1-2 days).
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are absorbed and excreted by the kidneys.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Renal excretion of water and electrolytes; dextrose is metabolized to CO2 and water. >90% of water and electrolytes are excreted renally; dextrose is fully metabolized.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Minimal (<5%); electrolytes are not significantly protein-bound; dextrose does not bind to proteins.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Electrolytes distribute to total body water (~0.6 L/kg); dextrose distributes to extracellular fluid initially (~0.2 L/kg) then intracellularly.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100% bioavailability.
Intravenous: 100% bioavailability.
No specific dose adjustment; monitor fluid and electrolyte status closely in renal impairment due to risk of volume overload and electrolyte disturbances.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances due to potential altered metabolism.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Intravenous infusion; rate based on weight: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, and 20 m L/kg/day for each kg above 20 kg.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Use with caution; consider lower infusion rates due to decreased renal function and risk of fluid overload; monitor electrolytes and renal function closely.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
Not for use in patients with hyperglycemia or certain electrolyte imbalances; solutions containing aluminum may be toxic with prolonged use in renally impaired patients.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Monitor serum electrolytes, fluid balance, blood glucose; risk of hyperglycemia, hypokalemia, fluid overload; avoid in patients with renal impairment or heart failure.
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hyperkalemia, hypernatremia, hyperglycemia, severe metabolic acidosis, anuria, or hypersensitivity to any component.
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No direct food interactions. However, dietary intake of electrolytes (e.g., potassium, sodium) should be considered in patients receiving this solution. Avoid high-potassium foods if hyperkalemia is a concern.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/third trimester: use as needed for fluid/electrolyte balance. Dextrose may cause maternal hyperglycemia, which can affect fetal glucose and insulin levels, potentially leading to fetal hyperinsulinism and neonatal hypoglycemia if maternal glucose is poorly controlled.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Isolyte R in Dextrose 5% components (dextrose, electrolytes) are normal constituents of breast milk. No known adverse effects. M/P ratio not applicable as dextrose and electrolytes are endogenous substances. Use is considered compatible with breastfeeding.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No specific dose adjustments required for pregnancy. However, due to increased plasma volume and glomerular filtration rate in pregnancy, individualize based on fluid and electrolyte needs. Monitor for hyperglycemia, which may require dose reduction or insulin therapy. Use caution in preeclampsia or impaired renal function.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
ISOLYTE R in Dextrose 5% is an isotonic solution used for fluid and electrolyte replacement. Monitor serum glucose and electrolytes, especially in diabetic patients. Avoid in patients with hyperglycemia, hyperkalemia, or hyperlactatemia. Use with caution in renal impairment. The solution contains 130 m Eq/L sodium, 4 m Eq/L potassium, 3 m Eq/L calcium, 1 m Eq/L magnesium, 109 m Eq/L chloride, 28 m Eq/L lactate, and 5% dextrose. It provides 170 kcal/L. Do not administer simultaneously with blood products through same line.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
Inform your healthcare provider if you have diabetes, kidney problems, or heart failure.,Report any signs of fluid overload (swelling, difficulty breathing) or electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,This solution contains sugar; monitor blood glucose if you have diabetes.,Do not use if the solution is cloudy or contains particles.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Electrolyte and fluid replacement; dextrose provides caloric support.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/th. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.